2023 Announcements

CLINUVEL
Posted by CLINUVEL
September 20, 2023

Appendix 3Y - Change of Director’s Interest Notice

CLINUVEL has entered a formal collaboration with four of the world’s leading...

Read More
CLINUVEL
Posted by CLINUVEL
September 19, 2023

CEO letter to shareholders

Melbourne, Australia, 19 September 2023 ASX: CUV Frankfurt Börse: UR9 Level 1...

Read More
CLINUVEL
Posted by CLINUVEL
September 13, 2023

CLINUVEL Confirms AGM Date

Melbourne, Australia, 13 September 2023 ASX: CUV Frankfurt Börse: UR9 Level 1...

Read More
CLINUVEL
Posted by CLINUVEL
September 12, 2023

CLINUVEL Vitiligo Expert Panel

CLINUVEL has entered a formal collaboration with four of the world’s leading...

Read More
CLINUVEL
Posted by CLINUVEL
September 5, 2023

SCENESSE® in adolescent EPP study

Melbourne, Australia, 5 September 2023 ASX: CUV Frankfurt Börse: UR9 Level 1...

Read More
CLINUVEL
Posted by CLINUVEL
August 30, 2023

Investor Webinar transcript

Melbourne, Australia, 30 August 2023 ASX: CUV Frankfurt Börse: UR9 Level 1...

Read More
CLINUVEL
Posted by CLINUVEL
August 29, 2023

Appendix 4G and Corporate Governance Statement

Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...

Read More
CLINUVEL
Posted by CLINUVEL
August 29, 2023

CLINUVEL delivering on a long-term strategy with increase in annual revenues, profit

Melbourne, Australia, 29 August 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...

Read More
CLINUVEL
Posted by CLINUVEL
August 29, 2023

Dividend/Distribution – CUV

Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...

Read More
CLINUVEL
Posted by CLINUVEL
August 29, 2023

Appendix 4E & Annual Report

Melbourne, Australia, 29 August 2023 ASX: CUV Börse Frankfurt: UR9 Level 1...

Read More
CLINUVEL
Posted by CLINUVEL
August 23, 2023

Annual Results – Investor Webinar

Melbourne, Australia, 28 August 2023 ASX: CUV XETRA-DAX: UR9 Level 1 ADR:...

Read More
CLINUVEL
Posted by CLINUVEL
August 15, 2023

Technical Note: DNA Damage and Repair

This Technical Note provides further detail on the current standards of care...

Read More
CLINUVEL
Posted by CLINUVEL
August 15, 2023

Afamelanotide Significantly Reduces DNA Damage in a Healthy Population

CLINUVEL has been awarded a five-year contract by the U.S. Department of...

Read More
CLINUVEL
Posted by CLINUVEL
July 26, 2023

SCENESSE® applied under five-year Veterans Affairs contract

CLINUVEL has been awarded a five-year contract by the U.S. Department of...

Read More
CLINUVEL
Posted by CLINUVEL
July 14, 2023

CLINUVEL secures IP for melanocortins to treat central nervous system disorders

CLINUVEL has secured a family of patents and patent applications relating to...

Read More